View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 15, 2021updated 12 Jul 2022 11:22am

SuperTrans appoints Australian firms for new drug trials to fight AMR

SuperTrans Medical has appointed Australian companies CMAX, Avance Clinical, and Agilex Biolabs for clinical trial research of a new drug in the battle against antimicrobial resistance (AMR).

SuperTrans Medical has appointed Australian companies CMAX, Avance Clinical , and Agilex Biolabs for clinical trial research of a new drug in the battle against antimicrobial resistance (AMR).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The World Health Organization (Who ) describes AMR as a ‘silent pandemic’ and one of the biggest threats to global health.

CMAX, Avance Clinical and Agilex Biolabs will serve as SuperTrans Medical ’s key clinical research partners for conducting the launch of Phase I human clinical trials in Australia this year for the company’s new antibiotic.

The drug makes use of SuperTrans Medical ’s Intelligent Repurposing technology, which was invented at Stanford University originally.

SuperTrans Medical CEO Dr Lewis Neville said: “Antibiotic-resistant infections are a serious threat to global health and with only four new classes of antibiotics introduced since the early 1960s, clinicians just don’t have enough to work with.

“With the highly promising safety and efficacy results we’ve seen to date, we believe our repurposed and retargeted antibiotic could bring a much-needed and new panacea to thwart these urgent threat pathogens.”

Recently, the company announced plans to start clinical trials in the country later this year for its lead indication, complicated Urinary Tract Infections (cUTIs), which represent one of the most frequent infectious diseases.

South Australia Trade and Investment Minister Stephen Patterson said: “Within the plan, clinical trials have been identified by industry as a key enabler for growth, and today’s announcement is a major win for the state, highlighting the vast opportunities in this fast-growing sector.”

CMAX will be responsible for the preparation and carrying out of the Phase I study at Royal Adelaide Hospital .

All the activities surrounding this trial will be managed and coordinated by Avance Clinical , and Agilex Biolabs would provide all the required bioanalytical services and support associated with it.

SuperTrans Medical ’s clinical trial will start in healthy volunteers late this year in Australia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena